full record print

Lipoprotein(a) and Benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol

author
corporate author
ODYSSEY Outcomes Committees and Investigators
statement of authorship
Gregory G. Schwartz, Michael Szarek, Vera A. Bittner, Rafael Diaz, Shaun G. Goodman, and on behalf of ODYSSEY Outcomes Committees and Investigators, [Margus Viigimaa et al.]
source
publisher
American College of Cardiology
journal volume number month
Vol. 78, 5
year of publication
pages
p. 421–433 : ill
url
ISSN
0735-1097
language
inglise
Reserch Group
Research group on diagnostics and treatment technologies of hypertension and atherosclerosis
Schwartz, G. G., Szarek, M., Bittner, V. A., Diaz, R., Goodman, S. G., ODYSSEY Outcomes Committees and Investigators, Viigimaa, M. et al. Lipoprotein(a) and Benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol // Journal of the American College of Cardiology (2021) Vol. 78, 5, p. 421–433 : ill. https://www.jacc.org/doi/epdf/10.1016/j.jacc.2021.04.102 https://doi.org/10.1016/j.jacc.2021.04.102